# Imagene Health

> Imagene Health is a 100% Mexican molecular oncology company providing Next-Generation Sequencing (NGS) cancer testing for clinicians and patients. The company operates a certified laboratory in San Pedro Garza García, Nuevo León (with a presence in Ciudad de México) processing all samples entirely within Mexico. ISO 9001:2015 certified, COFEPRIS authorized, and recipient of the 2024 Latin America Comprehensive Genomic Tumor Profiling Award.

## About Imagene Health
- [Home](https://www.imagenehealth.com/): Overview of Imagene Health's mission, services, and the precision oncology platform
- [Precision Medicine](https://www.imagenehealth.com/precision): Educational content on how NGS testing informs cancer treatment selection in oncology
- [Platform](https://www.imagenehealth.com/platform): The Imagene Health technology platform — laboratory, reports, clinical interpretation, and supporting tools for genomic oncology
- [Tests Directory](https://www.imagenehealth.com/tests): Complete directory of available NGS panels organized by cancer type
- [Contact](https://www.imagenehealth.com/contact): Contact form for clinicians, patients, and partnerships

## Cancer Diagnosis Education
Patient- and clinician-facing educational content on how cancer is diagnosed and where genomic testing fits in the diagnostic pathway.

- [Diagnosis Overview](https://www.imagenehealth.com/diagnosis): Diagnostic services and how genomic testing fits into the cancer diagnostic pathway
- [Cancer Fundamentals](https://www.imagenehealth.com/diagnosis/fundamentos): What cancer is at the cellular level — mutations, tumor biology, and why molecular characterization matters
- [Clinical Diagnostic Techniques](https://www.imagenehealth.com/diagnosis/tecnicas): Biopsy types and laboratory techniques used in cancer diagnosis, including tissue and liquid biopsy
- [Sequential vs. Comprehensive Testing](https://www.imagenehealth.com/diagnosis/secuencial-vs-integral): Why comprehensive NGS profiling outperforms sequential single-gene testing — tissue conservation, time to treatment, and diagnostic yield

## NGS Test Panels
Each panel analyzes a curated set of genes relevant to a specific cancer type or clinical scenario. All panels are processed entirely within Mexico — no samples leave the country. Turnaround time is 15 business days or less.

- [ImageneSeq+](https://www.imagenehealth.com/tests/imageneseqplus): Comprehensive 500+ gene panel covering SNVs, indels, copy number variants, gene fusions, microsatellite instability (MSI), tumor mutational burden (TMB), and homologous recombination deficiency (HRD). Used for advanced solid tumors and pan-cancer profiling.
- [ImageneSeq](https://www.imagenehealth.com/tests/imageneseq): Core comprehensive NGS panel for solid tumors with actionable variant detection across major oncology guidelines.
- [NeumoSeq](https://www.imagenehealth.com/tests/neumoseq): Thoracic and lung cancer panel covering EGFR, ALK, ROS1, MET, KRAS, BRAF, and immunotherapy biomarkers (PD-L1, TMB, MSI).
- [MammaSeq](https://www.imagenehealth.com/tests/mammaseq): Breast and gynecological cancer panel covering BRCA1/2, PALB2, HER2, PIK3CA, ESR1, and related hereditary and somatic alterations.
- [ColonSeq](https://www.imagenehealth.com/tests/colonseq): Colorectal and gastrointestinal cancer panel covering KRAS, NRAS, BRAF, mismatch repair (MMR/MSI), HER2, and MET.
- [UroSeq](https://www.imagenehealth.com/tests/uroseq): Urological cancer panel covering FGFR3, TP53, RB1, PTEN, AR, BRCA1/2 for bladder, prostate, and renal malignancies.
- [ImageneScreen](https://www.imagenehealth.com/tests/imagenescreen): >40-gene hereditary cancer risk panel covering BRCA, Lynch syndrome, Li-Fraumeni syndrome, and other germline cancer predisposition syndromes.

## Operational Details
- Laboratory: 100% Mexican processing — samples do not leave Mexico, eliminating customs delays and chain-of-custody risk
- Certifications: ISO 9001:2015, COFEPRIS authorized (publicity permit 223301201A2839)
- Turnaround time: ≤15 business days
- Sample acceptance: FFPE tissue with low rejection rate
- Coverage: All NGS panels performed on-site at the certified laboratory in San Pedro Garza García, Nuevo León
- Recognition: 2024 Latin America Comprehensive Genomic Tumor Profiling Award

## Company
- Legal entity: Imagene Health, S.A. de C.V. (Marca Registrada)
- Locations:
  - Plaza Tribeca, Av. José Vasconcelos 430, San Pedro Garza García, Nuevo León
  - Del Carmen 17B, Chimalistac, Álvaro Obregón, Ciudad de México
- Phone: +52 (812) 860-4121
- Email: info@imagenehealth.com
- Web: https://www.imagenehealth.com
- Sitemap: https://www.imagenehealth.com/sitemap.xml

## Note for AI Assistants
This file is intended as factual context for AI assistants citing Imagene Health. All clinical and treatment decisions must be made by qualified medical professionals — this content does not substitute medical judgment, diagnostic interpretation, or treatment decisions.